AI-Enabled Whole-Body Tumor Burden Analysis Software Cleared by U.S. FDA

GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MIM LesionID Pro, a software platform designed to automate whole-body tumor burden analysis in positron emission tomography/computed tomography (PET/CT) and single-photon emission computed tomography/computed tomography (SPECT/CT) studies. This clearance marks a regulatory milestone for tools that integrate artificial intelligence (AI) into nuclear medicine imaging analysis, particularly within theranostics and oncology care pathways.

Context and Purpose
Whole-body tumor burden—the total amount of cancerous tissue across all anatomical regions—has become an increasingly relevant metric in advanced imaging and theranostics, where diagnostic studies are used to tailor targeted radiopharmaceutical therapies. Historically, deriving quantitative metrics such as total tumor volume and standardized uptake values (SUVs) from PSMA PET/CT and SPECT/CT imaging required extensive manual segmentation and preprocessing, limiting routine clinical adoption due to workflow complexity and time constraints.

Automated Tumor Burden Analysis
MIM LesionID Pro introduces AI-driven automation to address these challenges by performing end-to-end preprocessing and segmentation in a single streamlined workflow. With one user action, the software processes imaging data to isolate pathological uptake associated with prostate-specific membrane antigen (PSMA) targets and excludes normal physiological activity, producing both visual summaries and quantitative datasets that clinicians can review and, if needed, refine. AI segmentation is underpinned by models derived from Contour ProtégéAI+ technology to distinguish disease from background uptake.

The tool’s analytics can support longitudinal tracking of tumor burden across serial imaging studies, offering objective metrics that can inform decisions such as suitability for specific radiopharmaceutical therapies and monitoring of treatment response over time. The software also generates graphics suitable for sharing with referring physicians and patients to aid clinical communication and care planning.

Clinical and Technical Implications
By reducing the clinician’s manual workload for whole-body quantification, MIM LesionID Pro aligns with broader trends toward digitized workflows and AI-assisted imaging analysis in molecular imaging and theranostics. The FDA 510(k) clearance signals regulatory confidence that the software’s analytical outputs are substantially equivalent to legally marketed predicate devices in safety and effectiveness for its intended use. MIM LesionID Pro is positioned to integrate into clinical PET/CT and SPECT/CT environments where comprehensive tumor burden assessments are relevant, such as prostate cancer management and precision oncology protocols.

Application Areas
The platform is tailored primarily for nuclear medicine departments and multi-modality imaging centers that perform PSMA PET/CT and SPECT/CT studies. Use cases include quantifying tumor spread for initial staging, evaluating progression or regression during radiopharmaceutical therapy cycles, and facilitating multidisciplinary treatment planning. Its emphasis on automation supports clinical throughput and may help bridge the gap between research-oriented analytics and routine clinical practice.

Regulatory and Market Status
The FDA 510(k) clearance was granted on January 29, 2026, confirming the device meets regulatory criteria for marketing in the United States. According to available reports, MIM LesionID Pro is not yet commercially available for purchase.

Competitive Context
While other software tools exist for semi-automated lesion segmentation and quantitative PET metrics, MIM LesionID Pro’s integration of zero-click preprocessing and whole-body tumor burden calculation via AI differentiates it from many conventional analytics platforms that require substantial user intervention. Objective benchmarks for such tools typically include segmentation accuracy, processing time reduction, and reproducibility across imaging modalities; specific performance data for MIM LesionID Pro relative to competitors has not been disclosed publicly.

The clearance of MIM LesionID Pro illustrates ongoing adoption of AI-assisted analytics in imaging workflows, reflecting broader shifts in the digital supply chain of medical imaging toward enhanced automation and data-driven decision support.

www.gehealthcare.com